Course Objectives
The objectives of the course include the discussion of the gaps of knowledge, of evidence and of organization in the field of pulmonary arterial hypertension. The stakeholders roundtable facilitates the promotion of proposals for the future.
Target Audience
Cardiologists, pediatric cardiologists, pulmonologists, internal medicine, rheumatologists, registered nurses.
Course Directors
N. Galiè (IT), G. Simonneau (FR)
Faculty
D. Badesch (USA), M.Beghetti (CH), A. El-Gazayerly (NL), G.Fischer (AT), A.Ghofrani (DE), S. Gibbs (UK), W. Gin-Sing (UK), D. Ivy (USA), N.Kim (USA), J. Newman (USA), W.Seeger (DE), O. Sitbon (FR), A. Torbicki (PL), R.Tuder (USA), JL Vachiery (BE), A.Vonk Noordegraaf (NL)
Programme
Friday 19 October
Session 1: N. Galiè - G. Simonneau
08:50 - 09:00 Welcome and Introduction - G. Simonneau
09:00 - 09:30 Pathology – R. Tuder
09:30 - 10:00 Pathobiology – R. Tuder
10:00 - 10:30 Genetics/Genomics – J. Newman
11:00 - 11: 30 Definitions and Classifications -
G. Simonneau
11:30 - 12:00 Pathophysiology - A.Vonk Nordegraaf
Session 2: S. Gibbs, O. Sitbon
13:00 – 13:30 Epidemiology and registries – O. Sitbon
13:30 – 14:00 Diagnosis and Prognosis – D. Badesch
14:00 – 14:30 Therapy – Standard of care - N. Galiè
14:30 – 15:00 Discussion
Session 3 JL. Vachiery, M. Beghetti
15:30 – 16:00 Therapy – Goals - O. Sitbon
16:00 – 16:30 New Design and New Therapies – A. Ghofrani
16:30 – 17:00 CTEPH – N Kim
17:00 – 17:30 PH due to Left Heart Disease and Chronic Lung Disease – W. Seeger
17:30 – 18:00 Pediatric PH – D. Ivy
Saturday 20 October
Session 4 – G 6 Meeting: A Torbicki, G. Fischer
09:00 – 09:30 Expectations from Patients – G. Fischer
09:30 – 10:00 Expectation from Nurses – W. Gin-Sing
10:30 – 11:00 The expectations of the Regulatory Agencies
A. El Gazayerly
11:00 – 11:30 The expectations of the Industry –
M. Ianosev
11:30 – 12:00 The expectations of healthcare providers -
D. Ivy
Session 5: N. Galiè - G. Simonneau
12:00–12:45 Roundtable discussion with invited representatives of healthcare providers and industry (M. Alison (Bayer), L. Varanese (Eli-Lilly), M. Ianosev (GSK), S. Teal (Pfizer), A.Maresta (Actelion), A. El Gazayerly
12:45 – 13:00 Summary of the meeting and perspectives
N. Galiè